Park City, Utah–(Newsfile Corp. – March 12, 2026) – Glafabra Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to GT-GLA-S03, its lead cell therapy candidate for classic Fabry disease. To view the full announcement, including downloadable images, bios, and more, click …
Read More »
Matribhumi Samachar English